Acute myocardial infarction associated with dietary supplements: Containing 1,3-dimethylamylamine and citrus aurantium

Texas Heart Institute Journal

Volumn 41, Issue 1, 2014, Pages 70-72

  Smith, Triston B ^a   Staub, Brian A ^a   Natarajan, Gayathri M ^a   Lasorda, David M ^a   Poornima, Indu G ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Citrus adverse effects; Coronary thrombosis chemically induced; Dietary supplements adverse effects standards; Myocardial infarction chemically induced therapy; Substance related disorders complications diagnosis; Synephrine toxicity; Therapy; Treatment outcome

Indexed keywords

4 METHYL 2 HEXYLAMINE; ACETYLSALICYLIC ACID; ATORVASTATIN; CREATINE KINASE; CREATINE KINASE MB; EPTIFIBATIDE; HEPARIN; PRASUGREL; TROPONIN T;

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ARTIFICIAL EMBOLISM; CASE REPORT; CONTINUOUS INFUSION; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; ELECTROCARDIOGRAPHY; EXERCISE; HEART MUSCLE INJURY; HEART VENTRICLE TACHYCARDIA; HUMAN; MALE; SINUS ARRHYTHMIA; SOUR ORANGE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; YOUNG ADULT;

AMINES; ANGINA PECTORIS; CITRUS; CORONARY ANGIOGRAPHY; CORONARY THROMBOSIS; DIETARY SUPPLEMENTS; HUMANS; MALE; MYOCARDIAL INFARCTION; PEPTIDES; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; PLATELET AGGREGATION INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84898888498     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: 10.14503/THIJ-12-2870     Document Type: Article

References (20)

1. U.S. Food and Drug Administration. Dietary supplements [Internet]. Available from: http://www.fda.gov/Food/Di etarySupplements/default.htm [updated 2013 Aug 28].
2. Whitehead PN, Schilling BK, Farney TM, Bloomer RJ. Impact of a dietary supplement containing 1,3-dimethylamylamine on blood pressure and bloodborne markers of health: a 10-week intervention study. Nutr Metab Insights 2012;5:33-9.
3. Gee P, Jackson S, Easton J. Another bitter pill: a case of toxicity from DMAA party pills. N Z Med J 2010;123(1327):124-7.
4. Thomas JE, Munir JA, McIntyre PZ, Ferguson MA. STEMI in a 24-year-old man after use of a synephrine-containing dietary supplement: a case report and review of the literature. Tex Heart Inst J 2009;36(6):586-90.
5. Lattman P, Singer N. Army studies workout supplements after deaths [news article on the Internet]. Available from: http://www.nytimes.com/2012/02/03/business/army-stud ies-workout-supplements-after-2-deaths.html [2012 Feb 2; cited 2013 Dec 23].
6. DMAA latest party pill substance to get ban [news article on the Internet]. Available from: http://www.3news.co.nz/ DMAA-latest-party-pill-substance-to-get-ban/tabid/423/ar ticleID/245691/Default.aspx [2012 Mar 8; cited 2013 Dec 23].
7. Starling S. UK begins DMAA crackdown [news article on the Internet]. Available from: http://www.nutraingredients. com/Regulation/UK-begins-DMAA-crackdown?utm_ source=copyright&utm_medium=OnSi te&utm_ campaign=copyright [2012 Feb 24; cited 2013 Dec 23].
8. McCarthy CG, Canale RE, Alleman RJ Jr, Reed JP, Bloomer RJ. Biochemical and anthropometric effects of a weight loss dietary supplement in healthy men and women. Nutr Metab Insights 2011;5:13-22.
9. Farney TM, McCarthy CG, Canale RE, Allman RJ Jr, Bloomer RJ. Hemodynamic and hematologic prof ile of healthy adults ingesting dietary supplements containing 1,3-dimethylamylamine and caffeine. Nutr Metab Insights 2011;5:1-12.
10. Fugh-Berman A, Myers A. Citrus aurantium, an ingredient of dietary supplements marketed for weight loss: current status of clinical and basic research. Exp Biol Med (Maywood) 2004;229(8):698-704.
11. Rossato LG, Costa VM, de Pinho PG, Carvalho F, de Lourdes Bastos M, Remiao F. Structural isomerization of synephrine influences its uptake and ensuing glutathione depletion in ratisolated cardiomyocytes. Arch Toxicol 2011;85(8):929-39.
12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42(6):1206-52.
13. Bent S, Padula A, Neuhaus J. Safety and efficacy of citrus aurantium for weight loss. Am J Cardiol 2004;94(10):1359-61.
14. Haaz S, Fontaine KR, Cutter G, Limdi N, Perumean-Chaney S, Allison DB. Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update. Obes Rev 2006;7(1):79-88.
15. Santana J, Sharpless KE, Nelson BC. Determination of parasynephrine and meta-synephrine positional isomers in bitter orange-containing dietary supplements by LC/UV and LC/ MS/MS. Food Chem 2008;109(3):675-82.
16. Health Canada relaxes P synephrine rules [news article on the Internet]. Available from: http://www.naturalproductsinsider. com/news/2011/10/health-canada-relaxes-rules-on-p-syn ephrine.aspx [2011 Oct 31; cited 2013 Dec 23].
17. Stohs SJ. Assessment of the adverse event reports associated with Citrus aurantium (bitter orange) from April 2004 to October 2009. J Funct Foods 2010;2(4):235-8.
18. Arbo MD, Schmitt GC, Limberger MF, Charao MF, Moro AM, Ribeiro GL, et al. Subchronic toxicity of Citrus aurantium L. (Rutaceae) extract and p-synephrine in mice. Regul Toxicol Pharmacol 2009;54(2):114-7.
19. Stohs SJ, Preuss HG, Shara M. A review of the receptor-binding properties of p-synephrine as related to its pharmacological effects. Oxid Med Cell Longev 2011;2011:482973.
20. Soni MG, Carabin IG, Griffiths JC, Burdock GA. Safety of ephedra: lessons learned. Toxicol Lett 2004;150(1):97-110.